Florida surgeon performs first U.S. robotic telesurgery 35 miles away

Key points

• The procedure took place on October 25, 2026, involving a 66-year-old male patient with prostate cancer.
• Dr. Vipul Patel, medical director of the Global Robotics Institute at AdventHealth, operated remotely from Celebration, Florida.
• The patient was located at AdventHealth Minneola, approximately 35 miles from Patel's location.
• A qualified surgical team, led by Dr. Marcio Moschovas, remained in the operating room with the patient to intervene if necessary.
• The event is part of an FDA-approved Investigational Device Exemption study, not a general clinical approval.
• Previous trials in this study included procedures between Orlando and Luanda, Angola, spanning over 7,000 miles.

Background

This development follows recent advancements in robotic medical technology, including a Canadian team's debut of a robotic-catheter hybrid for heart conditions in late October 2026. While those earlier experiments focused on procedural innovation within a single location, this Florida case represents a shift toward geographic distance as the primary variable in surgical robotics.

How outlets are covering it

ABC News and WFTV both confirm the successful completion of the surgery and the patient's positive recovery. However, WFTV provides more specific details on the on-site team, naming Dr. Marcio Moschovas and emphasizing the safety protocols regarding potential connectivity failures. ABC News highlights the broader implications for healthcare access, quoting Patel on reducing geographic barriers, while WFTV stresses that the FDA exemption does not equate to approval for widespread use. Both sources agree that this is the first documented instance of robotic telesurgery between two U.S. hospitals.

Why it matters

This milestone demonstrates the technical feasibility of remote robotic surgery within the United States, potentially reducing the need for patients to travel to specialized centers. If the ongoing study proves safe and effective, it could democratize access to complex surgical procedures, particularly for rural or remote populations. However, significant hurdles regarding cybersecurity and network stability must be resolved before broader implementation.

What to watch

Researchers will continue to analyze data from this and previous international trials to assess surgical outcomes, safety, and technical performance. The FDA will review the findings of the Investigational Device Exemption study to determine if the technology can move toward broader clinical approval. Additional procedures are expected as part of the ongoing investigation.